Current Aspects on the Therapeutics of Aging, Cellular Senescence and Neurodegenerative Diseases

Dear Colleagues,

Aging is an inevitable  process causing deteriorations in brain function. The aging process is described by the buildup of senescent cells and a decline in the ability to maintain essential homeostatic functions. An accumulation of damaged proteins, inflammation and cell death have all been linked to cellular aging, which has been linked with the development of neurodegenerative disorders. Alzheimer’s disease (AD) is an age-associated neurodegenerative disease (ND) which impairs memory and cognition, and affects behavioral and social activities. AD is the most common brain disease in the world, affecting 4–8% of the elderly population worldwide. Prevalence studies indicate that the global AD population will proliferate to 114 million by 2050. Increasing evidence has proved that autophagy–lysosomal pathway deficiency plays key roles in the pathogenesis of neurodegenerative disorders such as Alzheimer’s disease (AD) manifested by memory loss. At present, exploring cellular senescence as a potential therapeutic target for addressing neurodegenerative diseases has increasingly received the attention of researchers. Despite a plethora of laboratory as well as clinical research, there is a dearth of effective medicine. Therefore, it poses great challenges for researchers in the scientific community and medical experts to tackle the unresolved problems of disease pathogenesis and therapeutics for aging, cellular senescence and neurodegenerative diseases. Among the most promising strategies for drug discovery is employing traditional herbal medicine for the modulation of memory improvement and toxic protein degradation in aging, cellular senescence and neurodegenerative diseases therapy.

Dr. Ashok Iyaswamy
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• therapeutics
• neurodegenerative diseases
• aging
• cellular senescence
• Alzheimer’s disease
• Parkinson’s disease